The company is undergoing a review of strategic alternatives.
News & Analysis: Diplomat Pharmacy
2019 will be a rebuilding year for the specialty pharmacy.
Managing pharmacy benefits has been a lot harder than the specialty pharmacy expected.
The company's PBM business isn't paying off yet.
The specialty pharmacy is having trouble justifying its pharmacy benefit manager purchases.
President Trump's prescription drug plans appear to have spooked investors who own shares of the specialty pharmacy.
Investors are excited about the company's new leadership.
Investors fret after the company reports fourth-quarter results.
The company reaffirmed full-year 2017 guidance and provided an early look at expectations for 2018.
Investors aren't happy about the specialty pharmacy getting into the pharmacy benefit manager business.
Investors react to the huge run-up in price and the latest earnings report.